Skip to main content
. 2011 Aug 30;3:117–186. doi: 10.2147/CEOR.S14407

Table 8.

Comparison of the role of manufacturers in centralized reimbursement processes

Country Centralized reimbursement review/decision-making body (role) Refer technology topics for reimbursement consideration Participate in defining scope and/or protocol of assessment Comment on draft protocol Participate in consultations during assessment Submit information to group preparing assessment report Submit information to group preparing evaluation report Present views during committee meetings Nominate clinical and/or patient experts to make oral presentation to committee Attend committee meeting Comment on report and/or draft recommendations Appeal recommendations or decisions
Austria

  • Association of Austrian Social Security Institutions (decisions)55

  • Pharmaceutical Evaluation Board (recommendations)56

 Yes N/A N/A N/A N/A No No No No No Yes
Belgium

  • Minister of Social Affairs (decisions)

  • Drug Reimbursement Committee (recommendations)9,60

 Yes N/A N/A N/A N/A No No No No Yes Yes
Czech Republic

  • State Institute for Drug Control (decisions)65,176

 Yes N/A N/A N/A N/A No information found No information found No information found No information found No information found Yes
Denmark

  • Danish Medicines Agency (decisions)68,69,121

  • Reimbursement Committee (recommendations)68,121

 Yes N/A N/A N/A N/A No No No No Yes, if recommendation is negative Yes
Estonia

  • Ministry of Social Affairs (decisions)72

  • Pharmaceuticals Committee (recommendations)72

 Yes N/A N/A N/A N/A No information found No information found No information found No information found No information found No information found
Finland

  • Pharmaceuticals Pricing Board (decisions)73,74,76

  • Pharmaceuticals Pricing Board Expert Group (recommendations)75

 Yes N/A N/A N/A N/A No No No No Yes, if recommendation is negative Yes
France

  • Ministry for Health and Social Security (decisions)20,78

  • French National Authority for Health (recommendations)78

 Yes Yes (multiple technology appraisals)
N/A (single technology appraisals)		 No Yes (multiple technology appraisals)
N/A (single technology appraisals)		 No (multiple technology appraisals)
N/A (single technology appraisals)		 No No No No Yes Yes
Germany

  • Federal Joint Committee (decisions)19

  • Institute for Quality and Efficiency in Health Care (recommendations)19

 No Yes Yes No Yes No No No No Yes Yes (decisions only)
Greece

  • Transparency Committee in the Reimbursement and Medicinal Products (makes decisions)85

 Yes N/A N/A N/A N/A No information found No information found No information found No information found No information found No information found
Hungary

  • Ministers of Health and Finance

  • National Health Insurance Fund Administration (recommendations)88

 Yes N/A N/A N/A N/A No information found No information found No information found No information found No information found Yes
Ireland

  • Health Service Executive (decisions)91,92,147

 Yes N/A N/A N/A Yes No No No No Yes Yes
Italy

  • Italian Medicines Agency Technical Scientific Committee (decisions)94

  • Italian Medicines Agency Pricing and Reimbursement Committee (recommendations)95

 Yes N/A N/A N/A No Yes No No No Yes No
Norway

  • Norwegian Medicines Agency (decisions)98

  • Department of Pharmacoeconomics (recommendations)98

 Yes N/A N/A N/A No information found No information found No information found No information found No information found No information found Yes
Poland

  • Ministry of Health (decisions)99,166

 Yes N/A N/A N/A No information found No information found No information found No information found No information found No information found No information found
Portugal

  • Ministry of Health (decisions)

  • INFARMED (recommendations)36,44

 Yes N/A N/A N/A No information found No information found No information found No information found No information found No information found Yes
Scotland

  • National Health Service Scotland (decisions)30

  • Scottish Medicines Consortium (recommendations)

 Yes N/A N/A N/A No Yes No No No Yes Yes
Slovakia

  • Ministry of Health (decisions)

  • Reimbursement Committee for Medicinal Products (recommendations)105–107

 Yes N/A N/A N/A No information found No information found No information found No information found No information found No information found No
Spain

  • Ministry of Health Directorate General of Pharmacy and Health Products; Inter-Ministerial Pricing Commission (decisions)21,108

 No No No Yes Yes No No No No No No
Sweden

  • Dental and Pharmaceutical Benefits Board Expert Board (decisions)10,104,105

 Yes N/A N/A N/A N/A Yes Yes No No Yes Yes
Switzerland

  • Swiss Federal Office of Public Health (decisions)

  • Federal Drug Commission (recommendations)113,114

 Yes N/A N/A N/A N/A No information found No information found No information found No information found No information found Yes
The Netherlands

  • Ministry of Health, Welfare and Sport (decisions)

  • Dutch Healthcare Insurance Board Committee of the Dutch Healthcare Insurance Board (recommendations)31

 Yes N/A N/A N/A N/A No No No No No Yes
United Kingdom

  • National Institute for Health and Clinical Excellence (decisions)

  • Technology Appraisals Committee (recommendations)7

 Yes Yes (multiple technology appraisals)
N/A (single technology appraisals)		 No (multiple technology appraisals)
N/A (single technology appraisals)		 No (multiple technology appraisals)
N/A (single technology appraisals)		 Yes (multiple technology appraisals)
N/A (single technology appraisals)		 Yes (single technology appraisals)
N/A (single technology appraisals)		 No Yes No Yes Yes
Wales

  • Ministry for Health and Social Services (decisions)

  • All Wales Medicines Strategy Group (recommendations)120

 Yes N/A N/A N/A N/A Yes No No Yes Yes Yes